<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04057157</url>
  </required_header>
  <id_info>
    <org_study_id>17-10</org_study_id>
    <nct_id>NCT04057157</nct_id>
  </id_info>
  <brief_title>Post-market Assessment of Biodesign Dural Repair Grafts</brief_title>
  <official_title>Post-market Clinical Data Collection Plan for the Biodesign速 Dural and Duraplasty Grafts</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cook Research Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cook Group Incorporated</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical study is to gather post-market clinical evidence on the use of
      the Biodesign速 Dural and Duraplasty Grafts when used as a dura substitute of the dura mater.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 3, 2019</start_date>
  <completion_date type="Anticipated">December 18, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients without clinically relevant cerebrospinal fluid (CSF) leakage</measure>
    <time_frame>2 months</time_frame>
    <description>Clinically relevant CSF leakage is when it requires treatment (e.g., lumbar drain or surgical repair) or leads to an infection of the central nervous system (e.g., meningitis).</description>
  </primary_outcome>
  <enrollment type="Anticipated">128</enrollment>
  <condition>Cerebrospinal Fluid Leak</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Biodesign Dural or Duraplasty Repair Grafts</intervention_name>
    <description>Patients will receive the Biodesign Dural or Duraplasty Repair Grafts according to the Instruction for Use.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who have had dura mater repair using a Biodesign Dural or Duraplasty Graft.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Planned use of the Biodesign Dural or Duraplasty Graft.

        Exclusion Criteria:

          1. Age &lt;18 years

          2. Unable or unwilling to provide informed consent

          3. Life expectancy &lt;6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pernille Strandfelt</last_name>
    <phone>+45 56868449</phone>
    <email>Pernille.Strandfelt@cookmedical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Noah Shields</last_name>
    <phone>800-356-9208</phone>
    <phone_ext>321174</phone_ext>
    <email>noah.shields@cookmedical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>August 13, 2019</study_first_submitted>
  <study_first_submitted_qc>August 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2019</study_first_posted>
  <last_update_submitted>January 15, 2020</last_update_submitted>
  <last_update_submitted_qc>January 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dura mater repair</keyword>
  <keyword>cerebrospinal fluid leak</keyword>
  <keyword>CSF leak</keyword>
  <keyword>Biodesign速 Dural Repair Graft</keyword>
  <keyword>Biodesign速 Duraplasty Repair Graft</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebrospinal Fluid Leak</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Cook Research Incorporated (CRI) is fully committed to supporting the principles of responsible data sharing, including providing qualified scientific researchers access to deidentified, patient-level data from CRI clinical studies to conduct legitimate scientific research. Data underlying the results reported in this clinical study will be made available for request after publication of the results from this study and ending 5 years after initial publication. Interested researchers may review the &quot;Cook Research Incorporated Policy on Access to Clinical Study Data&quot; at https://www.cookresearchinc.com/extranet/data-access.html and submit a complete research proposal to request data access. Additional study documents (such as the study protocol) will be shared as needed if the data access request is granted. A data sharing agreement will be executed for access to deidentified patient-level data.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

